Human apolipoprotein A-IV (apoA-IV), discovered in 1970s, is a 46 kD glycoprotein exclusively synthesized and secreted by intestinal enterocytes [1] . e stimulated production of apoA-IV in response to lipid absorption is achieved by increased transcription of apoA-IV in the enterocytes [2] . Physiologically, apoA-IV circulates in both blood and lymph in a free form; a structural protein of chylomicron or a high-density lipoprotein (HDL) [3] . It is well recognized that apoA-IV is a satiety factor suppressing food intake [4] [5] [6] , and is involved in lipid metabolism [7] [8] [9] [10] . Recently, accumulating evidence has shown that apoA-IV has an endogenous anti-in ammatory e ect [11, 12] and is a potent endogenous antioxidant that protects against copper-induced oxidation of low-density lipoprotein (LDL) [13] and macrophage-mediated oxidation [14] . Over-expression of either human or mouse apoA-IV in transgenic mice confers signi cant protection against diet-induced atherosclerosis in cholesterol-fed animals and apoE-de cient mice have been shown previously [13, 15, 16] . ere is, however, little evidence to date that patients with coronary artery disease (CAD) have low serum apoA-IV levels [17] [18] [19] .
Acute coronary syndrome (ACS), acute cardiac events resulting from atherosclerosis, is related to rupture of coronary artery atherosclerotic plaques and subsequent thrombus formation [20, 21] . In ammation and oxidative stress also participate in the pathogenesis of ACS [22] [23] [24] . Clinically ACS spans a broad classi cation, including unstable angina pectoris (UAP) and acute myocardial infarction (AMI), and the latter refers to non-ST-elevation myocardial infarction (NSTEMI) and STelevation myocardial infarction (STEMI) [25] . Despite receiving appropriate treatments, ACS patients still have a high risk of death and disability [26] [27] [28] . is study was undertaken to assess the relation between apoA-IV plasma concentrations and ACS, to explore a potential and novel treatment target for ACS patients.
Materials and Methods

Study population
A total of 115 ACS patients (61 males and 54 females, aged 63.3 ± 10.7 years) admitted to the Institute of Cardiovascular Medicine, Xinqiao Hospital, which is a liated with the ird Military Medical University, were eligible for inclusion in this study. Exclusion criteria included the use of lipid-lowering medicine, a history of gastrointestinal surgery and renal impairment (serum creatinine > 105 μmol/L). An age-and gender-matched group of 68 control subjects (43 males and 25 females, aged 61.0 ± 7.0 years) from the Senior HealthChecking Centre, Southwest Hospital, which is also a liated to the ird Military Medical University, was studied. ese subjects had no history of either renal impairment or use of lipid-lowering medicine. e Local Ethics Committee of the ird Military Medical University approved the study protocol and the informed consent form. is study was conducted in accordance with the Declaration of Helsinki, and written consent was obtained from all participants.
De nition of ACS
Following the ACC/AHA 2007 Guidelines, UAP was de ned as manifesting at least one of the following presentations, without any rise of cardiac troponin I or elevated ST-segment on electrocardiograph: (1) angina at rest, (2) new-onset severe angina and (3) increasing angina (more frequent and longer in duration). NSTEMI was de ned as chest pain longer than 20 min with documented transient ST-segment depression (≥1 mm) or T-wave inversion (≥1 mm) in at least two contiguous leads and positive cardiac troponin I (cTnI) (>0.5 μg/mL). STEMI was de ned as chest pain longer than 20 min with STsegment elevation (≥1 mm) in at least two contiguous leads or new le bundle branch block, and elevated cTnI (>0.5 μg/mL).
Questionnaires
Information on cardiovascular risk factors, including history of current smoking, hypertension, diabetes, hypercuricemia and dyslipidemia, was obtained through review of medical records. Smoking was de ned as either "yes" (current smoker) or "no" (non-smoker). Hypertension was de ned as self-reported use of antihypertensive medicines or a diastolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg in the sitting position on at least three di erent occasions. Subjects with fasting blood glucose levels ≥7 mmol/L or on treatment with plasma glucose-lowering medications were classi ed as diabetics. Hyperuricemia was de ned as serum uric acid levels >420 mmol/L in males and >360 mmol/L in females. Dyslipidemia was de ned as follows: total cholesterol >5.69 mmol/L, triglycerides >1.68 mmol/L, LDL-cholesterol >3.1 mmol/L, or HDL-cholesterol <0.9 mmol/L. e New York Heart Association Class (NYHA class) was used to evaluate patients' functional status.
Blood collection and biochemical analysis
Blood samples were drawn for the purpose of diagnosis and treatment, and necessary biochemical parameters were measured by standard automated techniques in our hospital. Additionally, to prepare plasma samples for measuring apoA-IV, fasting whole blood was collected the following morning in one 2 mL tube containing K 3 EDTA to achieve a nal concentration of 1.735 mg/mL. ese samples were centrifuged (2,000 g for 15 min) immediately a er collection, and stored at -70˚C for further analysis. Human plasma apoA-IV concentrations were determined in duplicate using commercial sandwich enzyme-linked immunosorbent assay (ELISA) kits (Millipore, Billerica, MA, USA) in a blinded fashion. All plasma samples were measured within three months of collection. e doseresponse curve of this assay was established by a sigmoidal veparameter logistic equation.
e standard curve for human plasma apoA-IV concentration was created by using serial dilutions (1:64-1:2) of 4.3 ug/mL puri ed recombinant human apoA-IV from the ELISA kit according to the instructions. e intra-and inter-assay coe cients of variation (CV) were 4.6% and 12.3%, respectively.
Statistics
Continuous variables were presented as mean ± standard deviation (mean ± SD). Categorical variables were expressed as percentage or frequency.
e independent-samples t-test or one-way ANOVA were used to compare continuous variables, and categorical variables were compared by nonparametric chisquare test.
e Kolmogorov-Smirnov test was applied for identifying normally distributed variables. Results Table 1 shows the clinical characteristics of ACS patients and control subjects. e patients with ACS (N = 115) had statistically signi cant reduction in plasma apoA-IV levels when compared to gender-and age-matched control subjects (N = 68) (437.0 ± 157.5 μg/mL vs. 590.2 ± 183.7 μg/mL, P<0.001). e ACS group had higher percentages of the patients with hypertension and dyslipidemia. Concentrations of plasma HDL cholesterol, triglyceride and LDL cholesterol were signi cantly lower and thrombin time longer in controls than they were in the patients. ACS patients were further grouped according to cardiovascular risk factors (gender, smoking, hypertension, diabetes, hyperuricemia and dyslipidemia), and there was no signi cant di erence among subgroups (Table 2) . ese patients were classi ed by types of ACS, i.e., the UAP group (N = 99, 86.1%) and the AMI group (N = 16, 13.9%). Fig. 1 shows the di erences in plasma apoA-IV concentrations between control subjects and two types of ACS patients. ere seemed to be an obvious decreasing trend from the control subjects to patients with unstable angina pectoris (UAP) to acute myocardial infarction (AMI) patients. Two types of ACS patients had a markedly lower apoA-IV level compared to the control subjects (UAP vs. control, 457.3 ± 152.9 μg/mL vs. 590.2 ± 183.7μg/mL, P<0.001; AMI vs. control, 311.7 ± 127.8 μg/mL vs. 590.2 ± 183.7μg/mL, P<0.001). Moreover, the plasma apoA-IV concentration was signi cantly decreased in the AMI group compared with the UAP group (311.7 ± 127.8 μg/mL vs. 457.3 ± 152.9 μg/mL, P<0.01).
Plasma apoA-IV level was negatively associated with NYHA functional class (Fig. 2 ). In the current study, there were no class I patients among the ACS group. Compared to the control subjects, NYHA class II (N = 80, 69.6%) and class III/IV (N = 35, 27.8%) patients had decreased levels of plasma apoA-IV (class II vs. control, 467.2 ± 142.1 μg/mL vs. 590.2 ± 183.7 μg/mL, P<0.001; class III/IV vs. control, 368.1 ± 170.8 μg/mL vs. 590.2 ± 183.7 μg/mL, P<0.001). And there was a signi cant di erence between class III/IV and class II patients (368.1 ± 170.8 μg/mL vs. 467.2 ± 142.1 μg/mL, P<0.05).
A stepwise multivariate regression analysis was used to determine the factors related to plasma apoA-IV levels in ACS patients with a model that included all variables listed in Table  1 . e plasma apoA-IV concentrations were independently associated with di erent types of ACS (P = 0.022), NYHA functional classes (P = 0.027) and plasma brinogen levels (P = 0.040). e standardized coe cients were -0.214, -0.201 and -0.186, respectively, in the regression equation. is was consistent with the results from one-way ANOVA ( Fig. 1 and Fig. 2 ) in subgroup analyses according to ACS types and NYHA functional classes. Besides, brinogen levels were also independently relative to plasma apoA-IV concentrations in a stepwise multivariate regression model. us, a scatter dot plot with tting curve was used for further quantifying their relationship (Fig. 3) , and revealed a weak negative, but statistically signi cant, correlation between plasma apoA-IV levels and brinogen concentrations in ACS patients (Pearson correlation coe cient, r = -0.276; P = 0.003).
Discussion
In this study, compelling evidence of a relationship between low plasma apoA-IV concentrations and ACS is presented. Patients with ACS had a 26% lower apoA-IV concentrations when compared with the gender-and age-matched control subjects. is is the rst study suggesting an obvious decreasing trend of plasma apoA-IV levels from control subjects to patients with unstable angina pectoris (UAP) to acute myocardial infarction (AMI) patients, and demonstrating the negative association of plasma apoA-IV concentrations with NYHA functional classes.
ACS is related to rupture of coronary artery atherosclerotic plaques and subsequent thrombus formation [20, 21] . rombolytics may be administered or urgent primary coronary angioplasty may be performed if the ECG con rms changes suggestive of STEMI. sis; however, despite receiving appropriate treatment, ACS patients still have a high risk of death and disability [20, 25] . It is necessary to study further the pathogenic mechanisms of ACS and to identify novel therapeutic targets; therefore, the present study provided clinical signi cance to evaluate the relationship between apoA-IV plasma concentrations and ACS. is study further categorized ACS patients by type of ACS and NYHA class, and suggested a negative correlation between plasma apoA-IV concentrations and severity of ACS and NYHA classes based on reduced plasma apoA-IV levels in ACS patients compared with control subjects. ese ndings imply a role of apoA-IV involved in the pathogenesis of ACS and a potentially novel treatment target for ACS. It has been con rmed that apoA-IV has positive roles in lipid metabolism [7] [8] [9] [10] , anti-in ammation [11, 12] , antioxidation [13, 14] and anti-atherogenesis [15, 16] . ApoA-IV binds to peripheral cells, promotes cholesterol e ux and the formation of HDL by stimulating lecithin-cholesterol acyltransferase (LCAT) activity [29] , and transports cholesterol to the liver or steroidogenic organs where cholesterol could be metabolized, thus participating in reverse cholesterol transport pathways [8] . Moreover, it modulates cholesterol-ester transfer protein-mediated transfer of cholesteryl esters from HDL to LDL [9] , and activates lipoprotein lipase [10] , which hydrolyzes triglycerides in lipoprotein. It has been demonstrated that the expression of human apoA-IV in apoE-de cient mice decreases the secretion of pro-in ammatory cytokines and inhibits P-selectin expression that modulates leukocyte and platelet adhesive interactions [11, 12] . In addition, Ostos et al. found that oxidation parameters were reduced in apoA-IV/Ede cient mice compared with apoE0 mice [13] . It has been also suggested that apoA-IV may serve as an antioxidant in vi o, where the oxidation of lipoproteins by macrophages in the subendothelial space may play a key role in the development of atherosclerosis [14] and attenuate oxidant-induced apoptosis [30] . Previous in vitro and in vi o animal studies have demonstrated that overexpression of either human or mouse apoA-IV in transgenic mice protects against diet-induced atherosclerosis in cholesterol-fed animals and apoE-de cient mice [15, 16] .; however, the value of apoA-IV in atherosclerotic patients is unclear. Only three previous clinical studies have reported its potential role as a risk protecting factor for coronary artery disease (CAD) [17] [18] [19] . Kronenberg et al. demonstrated an association between low apoA-IV concentrations and CAD in Li et al. Decreased apoA-IV with ACS humans [17] , which was consistent with the result by Ezeh et al., who suggested that lipid-free apoA-IV may play a key role for its antiatherogenic e ect [18] . Wong et al. found that genetic variation in and around ApoA4, independent of the effects of triglyceride, is associated with risk of CAD [19] . Data has also been reported that show a correlation between apoA-IV levels and risk of CAD in type 2 diabetes [31] and hemodialysis patients [32] .
In addition to the properties listed above, the cleavage of lipid-free apoA-IV by matrix metalloproteinase-7, which is known to be expressed primarily at the border between the brous cap and lipid core in atherosclerotic lesions, might be an important step leading to the disruption of normal lipid metabolism and the induction of atherosclerosis [33] . Atherosclerosis, in ammation and oxidative stress are essentially pathophysiological process in ACS; therefore, the bene cial effects of apoA-IV in ACS could be reasonably explained.
AMI is mostly caused by occlusion of a coronary artery following the rupture of a vulnerable atherosclerotic plaque [24] . Compared with UAP patients, AMI patients are at a higher risk for processes with severe life-threatening thrombotic events and, for the rst time, our study provides evidence that patients with AMI have lower plasma apoA-IV levels. Vulnerability of the atherosclerotic plaque may be responsible for reduced plasma apoA-IV levels. As we all know, activation of platelets and white blood cells are involved in the rupture of vulnerable plaque [22, 34] . Our observations may relate to modulation of platelet and white blood cell activation. In fact, it has been indicated that the neutrophil/lymphocyte ratio is associated with apoA-IV concentrations [32] ; however, the roles of apoA-IV in platelet activation remains unknown.
Patients with heart failure o en su er from congestion of gastrointestinal organs [35] and apoA-IV originates from small intestine in humans. Small bowel dysfunction because of congestion may result in decreased production of apoA-IV from the enterocytes. is may be the reason why decreased apoA-IV levels were observed in NYHA class III/IV patients. Further studies are needed to clarify the physiological role of plasma apoA-IV in heart failure patients.
Our data also suggest a negative association between apoA-IV levels and brinogen concentrations. In a large individual participant meta-analysis, moderately strong associations were found between increased plasma brinogen levels and the risk of major adverse cardiovascular events (MACEs) [36] . is appeared to indirectly indicate the relationship between lower apoA-IV concentrations and risks of MACEs, including ACS. Fibrinogen participates in anticoagulation as an important part of brinolytic system. Whether human apoA-IV is involved in establishing a balance between coagulation, anticoagulation and brinolysis, thereby a ecting atherothrombosis, needs to be further clari ed.
Several limitations of this study should be considered: the study was an observational case-control design, only one center was involved and the sample size was relatively small. Whether the ndings could be extrapolated to other populations and other disease conditions is yet to be determined. Another point to note is that the samples were drawn close (in time) to the diagnosis in the study. Furthermore, although these results suggest apoA-IV may be involved in the pathogenesis of ACS, we can not exclude the possibility that the change in plasma apoA-IV levels may be a consequence of the acute phase response, particularly since blood samples were collected at only one time point close to the diagnosis of ACS. Serial measurements of plasma apoA-IV drawn over time could potentially address this issue.
In conclusion, the present study revealed that plasma apoA-IV levels were 1) signi cantly decreased in ACS patients relative to controls, 2) were signi cantly lower in AMI patients compared with UAP patients, and 3) were negatively correlated with NYHA class. Our results support further large and multi-centered studies to demonstrate the role of apoA-IV in the eld of cardiovascular medicine as a potential and novel treatment target for ACS.
